Nuo Therapeutics (AURX) Stock Statistics & Valuation Metrics

Nuo Therapeutics has a market cap or net worth of $46.83M. The enterprise value is $49.25M.

Nuo Therapeutics has 48,408,730 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nuo Therapeutics’s return on equity (ROE) is 2.63 and return on invested capital (ROIC) is -408.69%.

The current PE Ratio of Nuo Therapeutics is ―. Nuo Therapeutics’s PEG ratio is -10.00.

In the last 12 months, Nuo Therapeutics had revenue of 3.31M and earned -2.51M in profits. Earnings per share was -0.05.

In the last 12 months, operating cash flow was -1.65M and capital expenditures -45.72K, giving a free cash flow of -1.70M billion.

Nuo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Nuo Therapeutics upcoming earnings date is May 14, 2026, TBA (Not Confirmed).

Nuo Therapeutics as a current ratio of 1.06, with Debt / Equity ratio of -79.77%

In the past 12 months, Nuo Therapeutics has paid 0.00 in taxes.

Nuo Therapeutics EV to EBITDA ratio is -39.52, with an EV/FCF ratio of -81.82.

Nuo Therapeutics has $263.83K in cash and marketable securities with $1.10M in debt, giving a net cash position of -$840.12K billion.

Gross margin is 65.46%, with operating margin of -75.95%, and net profit margin of -75.82%.

The average price target for Nuo Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy